---
type: "Topics"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/topics/39567181.md"
description: "$XTALPI(02228.HK)SigNature Sciences National Major Science and Technology Project ListI. Basic Project InformationFull Project Name: Mechanism Analysis of Refractory Gastric Cancer and R&D Application of Novel Small Molecule Drug TargetsProject Level: National Major Science and Technology Project for Innovative Drug R&D (formerly "Major New Drug Development") (Highest-level national support in the pharmaceutical field)Project Initiation Time: 2025 (Project announced in January 2026)Lead Unit: Peking University Cancer HospitalCore Participant: SigNature Sciences (Shenzhen) Co., Ltd. (Dr. Zhang Haisheng as project leader)Other Participants: Nanjing University Gulou Hospital, Fudan University, GenHouse Bio, Xijing Hospital, Air Force Medical UniversityII. Funding ScaleCentral Government Funding: 30-50 million RMB (3-year term, the only national-level project in the gastric cancer field)Local + Matching Funds: Estimated 10-20 million RMBTotal Funding: 40-70 million RMBLeverage Effect: Mobilizing 3-5 times social capital, actual R&D investment can reach hundreds of millions of RMBIII. Core Pipeline and ProgressCore Drugs: SIGX1094 (FAK inhibitor, world's first targeted drug for diffuse gastric cancer), SIGX2649 (TEAD inhibitor)Clinical Stage: Phase I Clinical Trial (led by Professor Shen Lin's team at Peking University Cancer Hospital)Authoritative Qualifications: China-US IND, FDA Orphan Drug + Fast Track designation, 2025 Galen Prize nominationTechnology Platform: Organoid + AI (World's first drug of this paradigm to enter clinical trials)IV. Policy Significance (Major Implications)National Strategic Recognition: Highest-level national R&D project in the pharmaceutical field, signifying national endorsement for AI+Organoid technologyClinical Unmet Need: No effective targeted drug for diffuse gastric cancer, China accounts for nearly 50% of global casesIndustry Milestone: Incubated by Xtalpi, China's AI-based drug R&D enters the national strategic echelon"
datetime: "2026-03-27T04:09:57.000Z"
locales:
  - [en](https://longbridge.com/en/topics/39567181.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/39567181.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/39567181.md)
author: "[wolf-001](https://longbridge.com/zh-CN/profiles/15460724.md)"
---

> 支持的语言: [English](https://longbridge.com/en/topics/39567181.md) | [繁體中文](https://longbridge.com/zh-HK/topics/39567181.md)


# $XTALPI(02228.HK)SigNature Sciences National Major…


### 相关股票

- [XTALPI (02228.HK)](https://longbridge.com/zh-CN/quote/02228.HK.md)